Hereditary Cancer Testing Global Market Report 2024

Description

Hereditary Cancer Testing Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hereditary cancer testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hereditary cancer testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary cancer testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Test Type: Multi Panel Test; Single-site Genetic Test
2) By Indication: Breast Cancer; Ovarian Cancer; Colorectal Cancer; Other Indications
3) By End user: Hospital; Clinics; Diagnostic Centers
Companies Mentioned: Centogene NV; Ambry Genetics Inc.; Myriad Genetics Inc.; NeoGenomics Laboratories Inc.; Quest Diagnostics
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Hereditary cancer testing involves various testing methods designed for identifying specific hereditary cancer diseases and gene mutations associated with these diseases. These tests play a crucial role in assessing the risk of developing certain cancer types with a genetic predisposition, enabling a more comprehensive understanding of cancer risk for patients. The primary objective of hereditary cancer testing is early detection, allowing for proactive measures to minimize the risk and improve overall health outcomes for individuals.

There are two main types of tests for hereditary cancer such as multi-panel tests and single-site genetic tests. Multi-panel tests simultaneously examine multiple genes associated with different types of cancers. These panels can vary in size, ranging from three-panel tests targeting specific substances to more extensive panels with five, seven, or even 12 tests, providing a broader analysis of genetic risk factors. The decision on the number of tests conducted is based on the discretion of the tester. Hereditary cancer testing is applicable to detect various types of cancers, including breast cancer, ovarian cancer, colorectal cancer, and others. These tests are typically conducted in hospitals, clinics, and diagnostic centers.

The hereditary cancer testing market research report is one of a series of new reports from The Business Research Company that provides hereditary cancer testing market statistics, including hereditary cancer testing industry global market size, regional shares, competitors with a hereditary cancer testing market share, detailed hereditary cancer testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary cancer testing industry. This hereditary cancer testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hereditary cancer testing market size has grown rapidly in recent years. It will grow from $3.97 billion in 2023 to $4.43 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to the rising incidence of hereditary cancers, genetic counseling programs, government initiatives for cancer prevention, improved insurance coverage, understanding of gene-environment interactions, and patient advocacy and support groups.

The hereditary cancer testing market size is expected to see rapid growth in the next few years. It will grow to $6.7 billion in 2028 at a compound annual growth rate (CAGR) of 10.9%. The anticipated growth in the forecast period can be attributed to the expansion of targeted therapies, advancements in precision medicine, the rise in direct-to-consumer testing, global health initiatives, and progress in bioinformatics. Major trends expected in this period include advancements in genetic sequencing technologies, the integration of telemedicine and remote genetic counseling, the continued development of precision medicine and personalized treatment approaches, the creation of cancer risk assessment models, and the increasing emphasis on ethical and legal considerations in the field of genetic testing and personalized medicine.

The hereditary cancer testing market is experiencing substantial growth due to the increasing prevalence of hereditary cancer. As highlighted in a June 2022 article on hereditary cancer in clinical practice, approximately 10% of pancreatic cancer cases have a genetic background. Moreover, hereditary factors contribute to around 10% of all cancer cases, with an estimated 20% of cancer patients having a family history of cancer, as reported by SOPHiA Genetics in May 2021. The demand for hereditary cancer testing is escalating as it enables the detection of specific gene mutations associated with hereditary cancer syndromes, facilitating comprehensive cancer risk assessments. This trend underscores the pivotal role of hereditary cancer testing in addressing the challenges posed by hereditary cancer.

The hereditary cancer testing market is set to witness significant growth driven by the increasing overall burden of cancer. Cancer, characterized by abnormal cell growth, poses a substantial health challenge globally. Hereditary cancer testing emerges as a crucial tool in mitigating this burden by identifying individuals with a genetic predisposition to specific cancers. This allows for early interventions, personalized treatment strategies, and proactive preventive measures. According to the EU Science Hub's October 2023 article, new cancer cases rose by 2.3%, reaching 2.74 million in 2022, and cancer-related deaths increased by 2.4% compared to 2020. The surge in cancer cases highlights the growing need for hereditary cancer testing as part of a comprehensive approach to cancer management.

Technological innovation is a key trend influencing the hereditary cancer testing market, with major players focusing on advancements to maintain their market positions. In March 2022, Myriad Genetics, a prominent US-based genetic testing and precision medicine company, introduced a Polygenic Breast Cancer Risk Assessment Score for all ancestries as part of its MyRisk Hereditary Cancer test with RiskScore. This innovative approach offers a personalized breast cancer risk assessment to women without a previous breast cancer diagnosis, showcasing the industry's commitment to leveraging technology for enhanced testing capabilities and individualized risk evaluations.

Collaborations and partnerships are strategic initiatives undertaken by major companies to reinforce their positions in the hereditary cancer testing market. In August 2021, Lightbeam Health Solutions, a US-based healthcare company, entered into a partnership with Ambry Genetics, a hereditary cancer genetic testing company. This collaboration aims to integrate precision genetic testing data from Ambry Genetics into the Lightbeam application. By combining forces, the companies intend to empower organizations in predicting heightened risks for common cancers and chronic conditions within patient populations. Such collaborations highlight the industry's recognition of the importance of synergies to enhance the scope and impact of hereditary cancer testing services.

In January 2022, Exact Sciences, a U.S.-based molecular diagnostics company, successfully completed the acquisition of PreventionGenetics for approximately $190 million. This strategic acquisition enhances Exact Sciences' portfolio of advanced cancer tests by incorporating PreventionGenetics' comprehensive genetic testing offerings, creating a complementary synergy. PreventionGenetics brings to the table not only a diverse genetic testing portfolio but also valuable clinical lab capabilities, expertise, and foundational technology. This collaboration aims to accelerate the availability of Hereditary Cancer Testing (HCT) and extend the reach of genetic risk assessment for cancer and other diseases. PreventionGenetics is a U.S.-based genetic testing and DNA testing laboratory.

Major companies operating in the hereditary cancer testing market report are Centogene NV, Ambry Genetics Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics, PreventionGenetics, Fulgent Genetics Inc., Invitae Corporation, Medical Diagnostic Laboratories LLC, Natera Inc., Color Health Inc., CooperSurgical Inc., OPKO Health Inc., Illumina Inc., Laboratory Corporation of America Holdings, Pathway Genomics Corporation, Strand Life Sciences Private Limited, Progenity Inc., Myogenes Ltd., Associated Regional and University Pathologists Inc., 4baseCare, Biocartis Group NV, F. Hoffmann-La Roche AG, Medgenome Pvt. Ltd., Abbott Laboratories, Agilent Technologies Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Oxford Nanopore Technologies PLC, and PerkinElmer Inc.

North America was the largest region in the hereditary cancer testing market in 2023. The regions covered in the hereditary cancer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hereditary cancer testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hereditary cancer testing market includes revenues earned by entities by providing hereditary cancer testing for lung cancer, cervical cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, and uterine cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12765

1. Executive Summary

2. Hereditary Cancer Testing Market Characteristics

3. Hereditary Cancer Testing Market Trends And Strategies

4. Hereditary Cancer Testing Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Hereditary Cancer Testing Market Size and Growth

5.1. Global Hereditary Cancer Testing Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Hereditary Cancer Testing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Hereditary Cancer Testing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hereditary Cancer Testing Market Segmentation

6.1. Global Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Multi Panel Test
Single-site Genetic Test
6.2. Global Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Breast Cancer
Ovarian Cancer
Colorectal Cancer
Other Indications
6.3. Global Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital
Clinics
Diagnostic Centers

7. Hereditary Cancer Testing Market Regional And Country Analysis

7.1. Global Hereditary Cancer Testing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Hereditary Cancer Testing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hereditary Cancer Testing Market

8.1. Asia-Pacific Hereditary Cancer Testing Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hereditary Cancer Testing Market

9.1. China Hereditary Cancer Testing Market Overview
9.2. China Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hereditary Cancer Testing Market

10.1. India Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hereditary Cancer Testing Market

11.1. Japan Hereditary Cancer Testing Market Overview
11.2. Japan Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hereditary Cancer Testing Market

12.1. Australia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hereditary Cancer Testing Market

13.1. Indonesia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hereditary Cancer Testing Market

14.1. South Korea Hereditary Cancer Testing Market Overview
14.2. South Korea Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hereditary Cancer Testing Market

15.1. Western Europe Hereditary Cancer Testing Market Overview
15.2. Western Europe Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hereditary Cancer Testing Market

16.1. UK Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hereditary Cancer Testing Market

17.1. Germany Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hereditary Cancer Testing Market

18.1. France Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hereditary Cancer Testing Market

19.1. Italy Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hereditary Cancer Testing Market

20.1. Spain Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hereditary Cancer Testing Market

21.1. Eastern Europe Hereditary Cancer Testing Market Overview
21.2. Eastern Europe Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hereditary Cancer Testing Market

22.1. Russia Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hereditary Cancer Testing Market

23.1. North America Hereditary Cancer Testing Market Overview
23.2. North America Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hereditary Cancer Testing Market

24.1. USA Hereditary Cancer Testing Market Overview
24.2. USA Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hereditary Cancer Testing Market

25.1. Canada Hereditary Cancer Testing Market Overview
25.2. Canada Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hereditary Cancer Testing Market

26.1. South America Hereditary Cancer Testing Market Overview
26.2. South America Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hereditary Cancer Testing Market

27.1. Brazil Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hereditary Cancer Testing Market

28.1. Middle East Hereditary Cancer Testing Market Overview
28.2. Middle East Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hereditary Cancer Testing Market

29.1. Africa Hereditary Cancer Testing Market Overview
29.2. Africa Hereditary Cancer Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Hereditary Cancer Testing Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Hereditary Cancer Testing Market, Segmentation By End user, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hereditary Cancer Testing Market Competitive Landscape And Company Profiles

30.1. Hereditary Cancer Testing Market Competitive Landscape
30.2. Hereditary Cancer Testing Market Company Profiles
- 30.2.1. Centogene NV
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Ambry Genetics Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Myriad Genetics Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. NeoGenomics Laboratories Inc.
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Quest Diagnostics
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Hereditary Cancer Testing Market Competitive Benchmarking

32. Global Hereditary Cancer Testing Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Hereditary Cancer Testing Market

34. Hereditary Cancer Testing Market Future Outlook and Potential Analysis

34.1 Hereditary Cancer Testing Market In 2028 - Countries Offering Most New Opportunities
34.2 Hereditary Cancer Testing Market In 2028 - Segments Offering Most New Opportunities
34.3 Hereditary Cancer Testing Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer